Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 16/20 | 0.55 |
| ▸ | F11 | P03951 | 11/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 6/20 | 0.48 |
| ▸ | TPSB2 | P20231 | 6/20 | 0.48 |
| ▸ | PLG | P00747 | 2/20 | 0.48 |
| ▸ | PLAU | P00749 | 2/20 | 0.48 |
| ▸ | F7 | P08709 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F9 | P00740 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16397297 | 1.00 | CFD (0.55) | CFDF11KLKB1TPSB2PLG | |
| SCHEMBL17764442 | 0.90 | CFD (0.62) | CFDF11KLKB1TPSB2PLG | |
| SCHEMBL16396649 | 0.90 | CFD (0.62) | CFDF11KLKB1TPSB2PLG | |
| SCHEMBL16397292 | 0.87 | CFD (0.49) | CFDF11KLKB1TPSB2PLG | |
| SCHEMBL16397291 | 0.87 | CFD (0.49) | CFDF11KLKB1TPSB2PLG | |
| SCHEMBL16397673 | 0.87 | CFD (0.47) | CFDF11KLKB1TPSB2PLG | |
| SCHEMBL16397670 | 0.87 | CFD (0.47) | CFDF11KLKB1TPSB2PLG | |
| SCHEMBL17764229 | 0.85 | CFD (0.51) | CFDF11KLKB1TPSB2PLG | |
| SCHEMBL16396997 | 0.85 | CFD (0.51) | CFDF11KLKB1TPSB2PLG | |
| SCHEMBL16396901 | 0.84 | CFD (0.47) | CFDF11KLKB1TPSB2PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| EP-3022182-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | CFD 1/4885F11 17/4885KLKB1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.